Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): A review of empirical evidence

Harvard Review of Psychiatry

Volumn 17, Issue 1, 2009, Pages 24-34

  Horsfall, Jan ^a   Cleary, Michelle ^a   Hunt, Glenn E ^a,b   Walter, Garry ^b,c  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c New South Wales Government   (Australia)

Author keywords

Cognitive behavioral therapy; Contingency management; Dual diagnosis; Motivational interviewing; Severe mental illness; Social skills training; Substance misuse

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DISEASE SEVERITY; DRUG DEPENDENCE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ALCOHOLISM; BIPOLAR DISORDER; CHRONIC DISEASE; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; PATIENT CARE TEAM; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 60749128921     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220902724599     Document Type: Review

References (82)

1. Burnam MA, Watkins KE. Substance abuse with mental disorders: specialized public systems and integrated care. Health Aff 2006;25:648-58.
2. Drake RE, Goldman HH, Leff HS, et al. Implementing evidence-based practices in routine mental health service settings. Psychiatr Serv 2001;52:179-82.
3. Todd J, Green G, Harrison M, et al. Defining dual diagnosis of mental illness and substance misuse: some methodological issues. J Psychiatr Ment Health Nurs 2004;11:48-54.
4. Cleary M, Hunt GE, Matheson S, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2008 Jan 23:CD001088.
5. Cleary M, Hunt GE, Matheson S, Siegfried N, Walter G. Psychosocial treatment programmes for people with both severe mental illness and substance misuse. Schizophr Bull 2008;34:226-8.
6. Barrowclough C, Haddock G, Fitzsimmons M, Johnson R. Treatment development for psychosis and co-occurring substance misuse: a descriptive review. J Ment Health 2006;15: 619-32.
7. Bogenschutz MP, Geppert CM, George J. The role of twelve-step approaches in dual diagnosis treatment and recovery. Am J Addict 2006;15:50-60.
8. Donald M, Dower J, Kavanagh D. Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Soc Sci Med 2005;60:1371-83.
9. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehab J 2004;27:360-74.
10. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat 2008;34:123-38.
11. Mueser K, Drake R, Sigmon S, Brunette MF. Psychosocial interventions for adults with severe mental illnesses and cooccurring substance use disorders: a review of specific interventions. J Dual Diagn 2005;1:57-82.
12. Tiet QQ, Mausbach B. Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res 2007;31:513-36.
13. Tsuang J, FongTW, Lesser I. Psychosocial treatment of patients with schizophrenia and substance abuse disorders. Addict Disord Treat 2006;5:53-66.
14. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
15. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313-21.
16. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
17. Hall W, Degenhardt L. Prevalence and correlates of cannabis use in developed and developing countries. Curr Opin Psychiatry 2007;20:393-7.
18. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24:443-55.
19. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7.
20. De Leon J, SusceMT, Diaz FJ, Rendon DM, Velasquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry 2005;66:1447-55.
21. Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev 2007;27:494-510.
22. Bennett ME, Bellack AS, Gearon JS. Treating substance abuse in schizophrenia-an initial report. J Subst Abuse Treat 2001;20:163-75.
23. Carey MP, Carey KB, Maisto SA, Schroder KE, Vanable PA, Gordon CM. HIV risk behavior among psychiatric outpatients: association with psychiatric disorder, substance use disorder, and gender. J Nerv Ment Dis 2004;192:289-96.
24. Dickey B, Azeni H, Weiss R, Sederer L. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ 2000;3:27-33.
25. Hawton K, Sutton L,HawC, Sinclair J,Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005;187:9-20.
26. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54:253-64.
27. Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencingmedication compliance in inpatient treatment of psychotic disorders. Psychopharmacol 2006;187:229-36.
28. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003;28:48-54.
29. Potvin S, Pampoulova T, Mancini-Marie A, Lipp O, Bouchard RH, Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006;77:796-8.
30. Todd J, Green G, Harrison M, et al. Social exclusion in clients with comorbid mental health and substance misuse problems. Soc Psychiatry Psychiatr Epidemiol 2004;39:581-7.
31. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-39.
32. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007;164:402-8.
33. Cleary M, Hunt, GE, Matheson S, Walter G. The association between substance use and the needs of patients with psychiatric disorder, levels of anxiety, and caregiving burden. Arch Psychiatr Nurs 2008;22:375-85.
34. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
35. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987;2:1483-6.
36. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005;100:354-66.
37. Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand 1997;96:329-33.
38. Shaffer HJ, LaPlante DA, LaBrie RA, Kidman RC, Donato AN, Stanton MV. Toward a syndrome model of addiction: multiple expressions, common etiology. Harv Rev Psychiatry 2004;12:367-74.
39. Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry 2004;161:1426-32.
40. Cohen LR, Hien DA. Treatment outcomes for women with substance abuse and PTSD who have experienced complex trauma. Psychiatr Serv 2006;57:100-6.
41. Briere J, Woo R, McRae B, Foltz J, Sitzman R. Lifetime victimization history, demographics, and clinical status in female psychiatric emergency room patients. J Nerv Ment Dis 1997;185:95-101.
42. Brunette MF, Drake RE. Gender differences in patients with schizophrenia and substance abuse. Compr Psychiatry 1997;38:109-16.
43. Morrissey JP, Jackson EW, Ellis AR, Amaro H, Brown VB, Najavits LM. Twelve-month outcomes of trauma-informed interventions for women with co-occurring disorders. Psychiatr Serv 2005;56:1213-22.
44. Scheller-Gilkey G, Moynes K, Cooper I, Kant C, Miller AH. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res 2004;69:167-74.
45. Carey KB, Purnine DM, Maisto SA, Carey MP. Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-session motivation-based intervention. Behav Modif 2001;25:331-84.
46. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: applications to addcitive behaviors. Am Psychol 1992;47:1102-14.
47. Bellack AS, DiClemente CC. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999;50:75-80.
48. Kavanagh DJ, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004;23:151-5.
49. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003;39:189-202.
50. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2006;188:439-48.
51. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006;63:426-32.
52. Ries RK, Dyck DG, Short R, Srebnik D, Fisher A, Comtois KA. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatr Serv 2004;55:445-7.
53. Drebing CE, Van Ormer EA, Krebs C, et al. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. J Appl Behav Anal 2005;38:359-72.
54. Clark RE. Family support and substance use outcomes for persons with mental illness and substance use disorders. Schizophr Bull 2001;27:93-101.
55. Haddock G, Barrowclough C, Tarrier N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 2003;183:418-26.
56. MueserKT,Drake RE, Bond GR.Recent advances in psychiatric rehabilitation for patients with severemental illness. Harv Rev Psychiatry 1997;5:123-37.
57. Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance abuse disorders. J Nerv Ment Dis 1995;183:566-76.
58. Magura S, Laudet AB, Mahmood D, Rosenblum A, Vogel HS, Knight EL. Role of self-help processes in achieving abstinence among dually diagnosed persons. Addict Behav 2003;28:399-413.
59. Drake RE, McHugo GJ, Clark RE, et al. Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: a clinical trial. Am J Orthopsychiatry 1998;68:201-15.
60. McHugo GJ, Drake RE, Teague GB, Xie H. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv 1999;50:818-24.
61. Essock SM, Mueser KT, Drake RE, et al. Comparison of ACT and standard case management for delivering integrated treatment for co-occurring disorders. Psychiatr Serv 2006;57:185-96.
62. Brunette MF, Drake RE,Woods M, Hartnett T. A comparison of long-term and short-term residential treatment programs for dual diagnosis patients. Psychiatr Serv 2001;52:526-8.
63. De Leon G, Sacks S, Staines G, McKendrick K. Modified therapeutic community for homeless mentally ill chemical abusers: treatment outcomes.AmJDrug Alcohol Abuse 2000;26:461-80.
64. Sullivan CJ, McKendrick K, Sacks S, Banks S. Modified therapeutic community treatment for offenders with MICA disorders: substance use outcomes. Am J Drug Alcohol Abuse 2007;33:823-32.
65. Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmstetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006;32:464-73.
66. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006;188:237-42.
67. Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res 2004;66:115-24.
68. Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006;114:109-17.
69. Baker A, Bucci S, Lewin TJ, Richmond R, Carr VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Res 2005;134:241-50.
70. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-13.
71. Drake RE, McHugo GJ, Noordsy DL. Treatment of alcoholism among schizophrenic outpatients: 4-year outcomes. Am J Psychiatry 1993;150:328-9.
72. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. Am J Addict 1995;4:33-42.
73. Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr Serv 2003;54:1287-9.
74. Drake RE, Yovetich NA, Bebout RR, Harris M, McHugo GJ. Integrated treatment for dually diagnosed homeless adults. J Nerv Ment Dis 1997;185:298-305.
75. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders. A clinical trial. J Nerv Ment Dis 1993;181:86-90.
76. Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry 2000;61:361-7.
77. Schmitz JM, Averill P, Sayre S, McCleary P, Moeller FG, Swann A. Cognitive-behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study. Addict Disord Treat 2002;1:17-24.
78. Brown RA, Evans DM, Miller IW, Burgess ES, Mueller TI. Cognitive-behavioral treatment for depression in alcoholism. J Consult Clin Psychol 1997;65:715-26.
79. Charney DA, Paraherakis AM, Gill KJ. Integrated treatment of comorbid depression and substance use disorders. J Clin Psychiatry 2001;62:672-7.
80. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006;32:724-42.
81. Graham HL. Implementing integrated treatment for coexisting substance use and severe mental health problems in assertive outreach teams: training issues. Drug Alcohol Rev 2004;23:463-70.
82. Grella CE. Contrasting the views of substance misuse and mental health treatment providers on treating the dually diagnosed. Subst Use Misuse 2003;38:1433-46.